The potentials and limitations of neuro-biomarkers as predictors of outcome in neonates with birth asphyxia

Satriano, Angela; Pluchinotta, Francesca Romana; Gazzolo, Francesca; Serpero, Laura D.; Gazzolo, Diego

doi:10.1016/j.earlhumdev.2016.12.005

Cited by 22 publications

(18 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Particular importance has been attributed to the predictive value of S100B levels for the outcome of newborns, when clinical and radiological signs are still silent (for review, Satriano et al . ). In DS and spinocerebellar ataxia‐1 (SCA1), data are also available indicating a mechanistic role for the protein.…”

Section: S100b As An Active Factor In Neural Injurymentioning

confidence: 97%

“…In perinatal/pediatric medicine, the levels of S100B have been investigated in various biological fluids, including CSF, blood, amniotic fluid, urine, saliva, the latter resulting especially promising as non-invasive diagnostic tools (for review, Michetti et al 2012). Particular importance has been attributed to the predictive value of S100B levels for the outcome of newborns, when clinical and radiological signs are still silent (for review, Satriano et al 2017). In DS and spinocerebellar ataxia-1 (SCA1), data are also available indicating a mechanistic role for the protein.…”

Section: Congenital/perinatal Disordersmentioning

confidence: 99%

“…In fact, the evaluation of its levels in biological fluids resulted to be an important aid in clinical diagnosis when symptoms are present, in monitoring the trend of the disorder and eventual clinical outcomes, in guiding therapeutic decision making by enabling identification of patients likely to respond to a specific therapy and, as a consequence, in monitoring the response to therapeutic interventions. The evaluation of S100B levels in biological fluids as a biomarker of neural distress has been extensively investigated, is still the goal of active research, and has been the object of recent valuable reviews focusing different disorders (Astrand et al 2013;Chong 2016;Lai and Du 2016;da Rosa et al 2016;Satriano et al 2017;Thelin et al 2017a,b). Intriguingly, following early findings of S100B in melanocytes and melanoma tissue (Cocchia et al 1981) the protein has been extensively used as a biomarker for this disease both in blood (Guo et al 1995;Henze et al 1997) and in pathologic tissue (Springall et al 1983;Cochran et al 1993).…”

mentioning

confidence: 99%

See 2 more Smart Citations

The S100B story: from biomarker to active factor in neural injury

Michetti

D’Ambrosi

Toesca

et al. 2018

Journal of Neurochemistry

290

238

View full text Add to dashboard Cite

S100B is a Ca -binding protein mainly concentrated in astrocytes. Its levels in biological fluids (cerebrospinal fluid, peripheral and cord blood, urine, saliva, amniotic fluid) are recognized as a reliable biomarker of active neural distress. Although the wide spectrum of diseases in which the protein is involved (acute brain injury, neurodegenerative diseases, congenital/perinatal disorders, psychiatric disorders) reduces its specificity, its levels remain an important aid in monitoring the trend of the disorder. Mounting evidence now points to S100B as a Damage-Associated Molecular Pattern molecule which, when released at high concentration, through its Receptor for Advanced Glycation Endproducts, triggers tissue reaction to damage in a series of different neural disorders. This review addresses this novel scenario, presenting data indicating that S100B levels and/or distribution in the nervous tissue of patients and/or experimental models of different neural disorders, for which the protein is used as a biomarker, are directly related to the progress of the disease: acute brain injury (ischemic/hemorrhagic stroke, traumatic injury), neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis), congenital/perinatal disorders (Down syndrome, spinocerebellar ataxia-1), psychiatric disorders (schizophrenia, mood disorders), inflammatory bowel disease. In many cases, over-expression/administration of the protein induces worsening of the disease, whereas its deletion/inactivation produces amelioration. This review points out that the pivotal role of the protein resulting from these data, opens the perspective that S100B may be regarded as a therapeutic target for these different diseases, which appear to share some common features reasonably attributable to neuroinflammation, regardless their origin.

show abstract

Section: S100b As An Active Factor In Neural Injurymentioning

confidence: 97%

Section: Congenital/perinatal Disordersmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

The S100B story: from biomarker to active factor in neural injury

Michetti

D’Ambrosi

Toesca

et al. 2018

Journal of Neurochemistry

290

238

View full text Add to dashboard Cite

show abstract

“…There has been a dramatic increase in recent years in the number of studies focusing on neurobiomarkers (NBs) of central nervous system (CNS) injury [1][2][3][4][5][6][7][8][9][10][11]. The optimal NB should be reliable, easily and harmless to collect, reproducible and able to guide caregivers in daily practice.…”

Section: Introductionmentioning

confidence: 99%

Early predictors of perinatal brain damage: the role of neurobiomarkers

Bersani

Pluchinotta

Dotta

et al. 2019

Clinical Chemistry and Laboratory Medicine (CCLM)

Self Cite

View full text Add to dashboard Cite

The early detection of perinatal brain damage in preterm and term newborns (i.e. intraventricular hemorrhage, periventricular leukomalacia and perinatal asphyxia) still constitute an unsolved issue. To date, despite technological improvement in standard perinatal monitoring procedures, decreasing the incidence of perinatal mortality, the perinatal morbidity pattern has a flat trend. Against this background, the measurement of brain constituents could be particularly useful in the early detection of cases at risk for short-/long-term brain injury. On this scenario, the main European and US international health-care institutions promoted perinatal clinical and experimental neuroprotection research projects aimed at validating and including a panel of biomarkers in the clinical guidelines. Although this is a promising attempt, there are several limitations that do not allow biomarkers to be included in standard monitoring procedures. The main limitations are: (i) the heterogeneity of neurological complications in the perinatal period, (ii) the small cohort sizes, (iii) the lack of multicenter investigations, (iv) the different techniques for neurobiomarkers assessment, (iv) the lack of consensus for the validation of assays in biological fluids such as urine and saliva, and (v), the lack of reference curves according to measurement technique and biological fluid. In the present review we offer an up-to-date overview of the most promising developments in the use of biomarkers in the perinatal period such as calcium binding proteins (S100B protein), vasoactive agents (adrenomedullin), brain biomarkers (activin A, neuron specific enolase, glial fibrillary acidic protein, ubiquitin carboxyl-terminal hydrolase-L1) and oxidative stress markers.

show abstract

“…Additionally elements which have been well discussed in the literature were not seen as priorities or even on the wider landscape in this exercise. These include measuring long-term outcomes within this population,28 improving neuroimaging29 and point-of-care testing in order to detect and aid management of neurological insults,30 among others. The difficulty that any methodology has in trying to draw out possible areas of priority will always be that other areas that show promise will be missed.…”

Section: Discussionmentioning

confidence: 99%

Designing the landscape for technological development in neonatal neurocritical care

et al. 2018

View full text Add to dashboard Cite

ObjectivesTo identify current ‘gaps’ in clinical practice or therapeutic knowledge of the care of neonatal neurointensive care patients and to determine the impact healthcare technologies can have on improving outcomes.DesignThe Cambridge Institute for Manufacturing’s (IfM) roadmapping methodology.SettingCambridge, UK.Participants16 delegates were selected through professional networks. They provided coverage of academia and clinical skills, as well as expertise in neonatology, engineering and technology development.Main outcome measuresA ‘strategic landscape’ has been developed with ‘landmarks’ identified as ‘trends or drivers’, ‘patient pathway experience and unmet needs’ and ‘enabling project or resources’. Priorities were voted on by delegates.Results26 strategic ‘landmarks’ were identified, and of these 8 were considered ‘trends or drivers’, 8 ‘patient pathway experience and unmet needs’ and 10 as ‘enabling project or resources’. Of these, five priorities for the future of neonatal neurocritical care were identified by a voting process: real-time video monitoring for parents; individualised management of preterm infants in neonatal neurocritical care based on real-time multimodal monitoring; continuous electroencephalogram monitoring for early seizure diagnosis; neuroprotection: understanding basic mechanisms; and sleep measurement.ConclusionsThrough the use of the IfM methodology, a list of priorities has been developed for future work into improving the experience and possible outcomes of newborn infants with brain injuries and their families. While not an exhaustive list, it provides the beginning for a national conversation on the topic.

show abstract

The potentials and limitations of neuro-biomarkers as predictors of outcome in neonates with birth asphyxia

Cited by 22 publications

References 59 publications

The S100B story: from biomarker to active factor in neural injury

The S100B story: from biomarker to active factor in neural injury

Early predictors of perinatal brain damage: the role of neurobiomarkers

Designing the landscape for technological development in neonatal neurocritical care

Contact Info

Product

Resources

About